AZN - Oxford Biomedica expects COVID-19 vaccine revenues from AstraZeneca in excess of £100M

Oxford Biomedica (OXBDF) upgrades financial guidance for supply agreement with AstraZeneca (AZN) for manufacturing of COVID-19 vaccine.The company is raising its guidance for revenues from AstraZeneca to be in excess of £100M from £50M, and as a result expects significant growth in Group Operating EBITDA in the year ending 2021. Oxford Biomedica announced an 18 month supply agreement with AstraZeneca in September 2020 for manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.

For further details see:

Oxford Biomedica expects COVID-19 vaccine revenues from AstraZeneca in excess of £100M